Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
NORINYL 1+35 28-DAY is an oral contraceptive tablet containing norethindrone and ethinyl estradiol, approved in 1974. It prevents pregnancy through hormonal suppression of ovulation and is indicated for contraception in women of reproductive age.
Product faces moderate competitive pressure (30%) in a mature contraceptive market with declining brand-specific investment likely.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
NORINYL 1+35 offers limited career growth due to its LOE-approaching status and mature market position. Roles are defensive, focusing on market share retention, payer negotiations, and operational efficiency rather than innovation or expansion.
Worked on NORINYL 1+35 28-DAY at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.